• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » BioClinica appoints Andrzej Dzik-Jurasz as its new medical director

BioClinica appoints Andrzej Dzik-Jurasz as its new medical director

September 28, 2011 By MassDevice

BioClinica Appoints Senior Medical Director, Dr. Andrzej Dzik-Jurasz

New Position Expands Scientific Coverage for MRI Imaging and Oncology

NEWTOWN, Pa.–(BUSINESS WIRE)–BioClinica®, Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced the appointment of Andrzej (Andy) Dzik-Jurasz, M.D., Ph.D. as Senior Medical Director for Medical Affairs, a newly created position. Dr. Dzik-Jurasz brings more than 15 years of clinical, radiological and pharmaceutical industry experience with major pharmaceutical companies such as Novartis Pharmaceuticals and GlaxoSmithKline.

“He will be responsible for leading our global oncology strategy, including the development and implementation of new offerings to support our clients’ clinical studies. Andy’s expertise in MRI imaging also provides additional depth for our imaging clientele.”
“Dr. Dzik-Jurasz’s appointment to this newly created position will help support BioClinica’s growth initiatives within our imaging core lab solutions business,” said Mark Weinstein, CEO of BioClinica. “He will be responsible for leading our global oncology strategy, including the development and implementation of new offerings to support our clients’ clinical studies. Andy’s expertise in MRI imaging also provides additional depth for our imaging clientele.”

Dr. Dzik-Jurasz is widely published in radiology with more than 40 publications in clinical and research journals. His academic and pharmaceutical industry experience has focused on imaging in clinical drug development. He has participated in all facets of the clinical trial process from Phase I to IV, with particular expertise in the field of oncology.

Dr. Dzik-Jurasz will report to Colin Miller, Ph.D. FICR CSci, Senior Vice President of Medical Affairs, who added, “Andy is a gifted and disciplined researcher who will make an immediate contribution to BioClinica’s culture of excellence and innovation for clinical trial support. His exceptional qualifications as a physician investigator combine an impressive scientific track record with a passion for the use of imaging in drug development. We are extremely pleased to have him join our team.”

Dr. Dzik-Jurasz joins BioClinica from Novartis where he held the position of Executive Director, Global Head Oncology Translational Imaging. Prior to that he was Vice President of Clinical Development for Point Therapeutics; Head of Imaging for Epix Pharmaceuticals, and Senior Director in Translational Medicine and Technology at GlaxoSmithKline. Dr. Dzik-Jurasz received his medical degree from Westminster Medical School, London, UK, and his Ph.D. from the Institute of Cancer Research, London, UK. He is a Fellow of the Royal College of Surgeons of England and Fellow of the Royal College of Radiologists.

Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on twitter at http://twitter.com/bioclinica.

About BioClinica, Inc.

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com

Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company’s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

Contacts

BioClinica, Inc.
Jim Dorsey, 267-757-3040
or
Diccicco Battista Communications
Trade Media – Rachel Summers
484-342-3600
or
Porter, LeVay & Rose, Inc.
Investor Contact – Michael Porter
Financial Media – Bill Gordon
212-564-4700

Filed Under: Uncategorized Tagged With: BioClinica Inc., Press Release

In case you missed it

  • EchoNous partners with Samsung on AI-guided ultrasound
  • RefleXion expands footprint through multi-system contract with Select Healthcare
  • Report: 3M faces losses of $100B in earplug lawsuits
  • Caregility, Eko partner to bring smart stethoscope to telehealth platform
  • Henry Schein makes $400M increase to share repurchase plan
  • Tandem Diabetes Care delivers 1 million insulin boluses using t:connect mobile app
  • CathVision closes $7.2M financing round for electrophysiology recording tech
  • Verily’s Onduo, Sword Health collaborate on virtual care
  • FDA clears expanded labeling for Preceptis Medical’s ear tube system
  • KeyCare raises $24M for virtual care platform
  • FDA says 44 more deaths have been reported in Philips ventilator recall
  • Paragonix reaches milestone of 2,000 organs preserved, transported for transplantation
  • Axonics expands IP portfolio with new patents
  • BD, Accelerate Diagnostics partner on rapid antibiotic testing
  • FDA clears VySpine’s VyPlate anterior cervical plate system
  • Technical Brief – “Understanding the Extensive OEM Benefits of Total Linear Motion Solutions.”
  • Exactech launches total hip arthroplasty system

RSS From Medical Design & Outsourcing

  • MIT engineers fabricate chip-free, wireless e-skin
    MIT engineers have developed a new wireless, wearable sensor without semiconductors or batteries in what they say is a first step toward chip-free wireless sensors. This electronic skin — or e-skin — is a flexible, semiconducting film that MIT describes as a sort of electronic Scotch tape. The device has an ultrathin gallium nitride film… […]
  • Owens & Minor and Allina Health partner on supply chain resiliency
    Owens & Minor (NYSE: OMI) and Minneapolis-based Allina Health are partnering on what they call a “unique integrated service model for supply chain resiliency.” An Owens & Minor distribution center that has been in operation for more than 25 years in Moundsview, Minnesota will serve as the integrated service center powering the model, the companies… […]
  • Chronic pain researchers say sound and electrical stimulation has treatment potential
    University of Minnesota researchers are using sound and electrical stimulation to treat chronic pain and other sensory disorders without pharmaceutical drugs. The combination of sound and stimulation activates the brain’s somatosensory cortex, according to a study on guinea pigs published in the Journal of Neural Engineering. Also known as the tactile cortex, the somatosensory cortex is… […]
  • What Laura Mauri learned from a ‘firestorm’ in her first months at Medtronic
    Dr. Laura Mauri faced a monumental moment with former Medtronic CEO Omar Ishrak shortly after she joined the company as VP of global clinical research and analytics. It was late 2018, and Mauri — who’s now an SVP and the chief scientific, medical and regulatory officer at Medtronic (NYSE: MDT) — was in a meeting… […]
  • Senators seek post-market FDA study of pulse oximeters and skin color
    Democratic U.S. senators are prodding the FDA to launch a post-market study of pulse oximeters due to unreliable performance for patients with dark skin. Pulse oximeters estimate blood oxygen levels (SpO2) and pulse rates in patients using infrared light — usually on a fingertip — at home or in clinical settings. Blood oxygenation is one… […]
  • TE Connectivity opens global medical device prototyping center in Ireland
    TE Connectivity (NYSE:TEL) today announced it opened its global Propelus Prototype Center for medical devices in Galway, Ireland. The $5 million rapid prototyping center was built into its existing manufacturing site in Galway and directly connects TE engineers with customers to reduce development time and increase speed to market for lifesaving and life-improving medical devices. Propelus… […]
  • Contract manufacturer Minnetronix Medical launches its first in-house product, MindsEye
    Minnetronix Medical has launched MindsEye, making it the first medical device that the contract developer and manufacturer has conceived and commercialized. St. Paul-based Minnetronix Medical’s MindsEye is the first expandable brain access port on the market. The FDA cleared the device under the 510(k) pathway in August 2020. The minimally invasive device gives neurosurgeons deep… […]
  • What’s next for Jennifer Fried after leaving Explorer Surgical?
    Explorer Surgical co-founder Jennifer Fried has resigned from the company after selling it to Global Healthcare Exchange in October. Fried announced her departure last week on LinkedIn, saying she’s preparing for her next professional chapter. “It’s bittersweet — I’m so proud of everything our team has built and accomplished,” Fried wrote. “The time has flown… […]
  • The 24 best medical device innovations of 2022
    The Galien Foundation recently announced its nominees of medical device innovations for its 2022 Prix Galien USA awards. There are 24 medical technologies nominated for the annual award this year, up from 18 nominees in 2021. The Galien Foundation’s annual Prix Galien awards highlight devices, biotechnology and pharmaceutical products designed to improve the human condition.… […]
  • FDA issues new COVID-19 testing guidance to avoid false negatives
    COVID-19 testing should be repeated following a negative result on any antigen test, the FDA said in a move that could increase demand for diagnostics manufacturers. The latest guidance from the federal health agency is for negative COVID-19 antigen test results regardless of the presence or absence of symptoms. The federal agency said recent studies… […]
  • Confluent Medical expands Costa Rica manufacturing footprint for nitinol, complex catheter production
    Confluent Medical Technologies this week announced the opening of its new addition to its Costa Rica manufacturing facility. The expansion adds 66,000 sq. ft to its large-scale manufacturing center of excellence in Alajuela, Costa Rica to expand Confluent’s capacity for nitinol component processing and complex catheter manufacturing. “Confluent has experienced consistent and strong growth in… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy